Finanzen von BioRestorative Therapies Inc (BRTX)BRTXBioRestorative Therapies Inc

Evaluating the bottom line, BioRestorative Therapies Inc maintains a gross margin of 68.13%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -14612.57%, while the net margin is -9298.25%. These profitability ratios, combined with a Return on Equity (ROE) of -241.50%, provide a clear picture of how effectively BRTX converts its operational activities into shareholder value.

In the context of the broader market, BRTX competes directly with industry leaders such as AMIX and ITOC. With a market capitalization of $5.76M, it holds a significant position in the sector. When comparing efficiency, BRTX's gross margin of 68.13% stands against AMIX's N/A and ITOC's 79.03%. Such benchmarking helps identify whether BioRestorative Therapies Inc is trading at a premium or discount relative to its financial performance.

BRTX has shown declining revenue and increasing net losses, with total revenue of only 233600 USD in Q3 2024 and a gross margin that has fluctuated significantly, dropping to 68.13% in Q1 2026. The company has been operating at a loss with a net income of -2154405 USD in Q1 2026.